TIMOGLOBULINA 5 mg/ml

MULTICENTER, RANDOMIZED STUDY TO EVALUATE THE EFFICACY OF INDIVIDUALIZATION OF IMMUNOLOGICAL RISK BASED ON SELECTIVE BIOMARKERS (HLA EPLETH DISPARITY AND IFN-γ ELISPOT) TO OPTIMIZE IMMUNOSUPPRESSIVE TREATMENT IN LIVING DONOR KIDNEY TRANSPLANT PATIENTS (BIOIMMUN)

Use of tacrolimus and MTOR inhibitors with anticipatory therapy vs. tacrolimus and mycophenolic acid with universal prophylaxis in renal recipients at high risk of post-transplant cytomegalovirus. Phase IV clinical trial (TIMTOR STUDY).